Collection of Tissue Samples for Study of Multidrug Resistance
Completed
Conditions studied: Breast Carcinoma, Breast Cancer, Medullary Thyroid Carcinoma
In brief
Background: Resistance to cancer chemotherapy develops in patients, rendering certain treatments ineffective. Despite much research, the prevailing cause of drug resistance is not known. One mechanism for drug resistance involves a protein called P-glycoprotein, or Pgp, which reduces the effectiveness of cancer treatments by "pumping" anti-cancer drugs out of tumor cells where they are supposed to work against the disease. Objectives: To identify and evaluate more thoroughly the roles of Pgp and other substances in mediating drug resistance. Eligibility: Patients enrolled in clinical trials of cancer therapies at the Children's Hospital of Pittsburgh; Cancer Centers of Carolinas; Arizona Clinical Research Center; University of Copenhagen; and Herlev Hospital, Copenhagen who have consented to the use of blood, tissue, or tumor samples for laboratory studies. Design: Blood, tumor, and tissue samples are collected from participants and sent to the NCI for various laboratory analyses. ...
Key facts
- Study ID
- NCT00880503
- Run by
- National Cancer Institute (NCI)
- People needed
- 325
- Starts
- 2003-12-19
- Expected to finish
- 2018-02-08
- Last updated by the study team
- 2019-12-16
Who can join
Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.
You may not qualify if…
- None anticipated at this time.
Where it is running
- Childrens Hospital, Pittsburgh — Pittsburgh, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.